Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 8, 2018. The report serves as a transaction notification regarding insider trading activity rather than a financial results announcement.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. It solely reports on a specific securities transaction.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882)
- Transaction Type: Sale
- Volume: 40,000 shares
- Price: £15.9462 per share
- Transaction Date: August 7, 2018
- Exchange: London Stock Exchange (XLON)
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a routine sale of shares by a Person Discharging Managerial Responsibilities (PDMR).
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a statutory disclosure of a transaction executed by Ms. C. Thomas, SVP of Human Resources.
Investor Verification Checklist
- Verify the total shareholding of Ms. C. Thomas post-transaction to assess remaining exposure.
- Confirm the market price of GSK shares on August 7, 2018, to validate the transaction price of £15.9462.
- Review subsequent filings to determine if this sale was part of a pre-arranged trading plan.